CHEBI:5613 - haloperidol

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name haloperidol
ChEBI ID CHEBI:5613
Definition A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C21H23ClFNO2
Net Charge 0
Average Mass 375.86400
Monoisotopic Mass 375.140
InChI InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
InChIKey LNEPOXFFQSENCJ-UHFFFAOYSA-N
SMILES OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1
Roles Classification
Biological Role(s): dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
Application(s): dopaminergic antagonist
A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
antidyskinesia agent
Any compound which can be used to treat or alleviate the symptoms of dyskinesia.
antiemetic
A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
first generation antipsychotic
Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.
serotonergic antagonist
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing haloperidol (CHEBI:5613) has role antidyskinesia agent (CHEBI:66956)
haloperidol (CHEBI:5613) has role antiemetic (CHEBI:50919)
haloperidol (CHEBI:5613) has role dopaminergic antagonist (CHEBI:48561)
haloperidol (CHEBI:5613) has role first generation antipsychotic (CHEBI:65190)
haloperidol (CHEBI:5613) has role serotonergic antagonist (CHEBI:48279)
haloperidol (CHEBI:5613) is a aromatic ketone (CHEBI:76224)
haloperidol (CHEBI:5613) is a hydroxypiperidine (CHEBI:48590)
haloperidol (CHEBI:5613) is a monochlorobenzenes (CHEBI:83403)
haloperidol (CHEBI:5613) is a organofluorine compound (CHEBI:37143)
haloperidol (CHEBI:5613) is a tertiary alcohol (CHEBI:26878)
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
INNs Sources
haloperidol KEGG DRUG
haloperidolum ChemIDplus
Synonyms Sources
1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine ChemIDplus
4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone NIST Chemistry WebBook
4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone NIST Chemistry WebBook
4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone NIST Chemistry WebBook
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one IUPHAR
γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone NIST Chemistry WebBook
Brand Name Source
Haldol KEGG DRUG
Database Links Databases
1353 DrugCentral
BE577977 Patent
C01814 KEGG COMPOUND
D00136 KEGG DRUG
DB00502 DrugBank
GB895309 Patent
Haloperidol Wikipedia
LSM-3512 LINCS
US3438991 Patent
View more database links
Registry Numbers Types Sources
331267 Beilstein Registry Number Beilstein
331267 Reaxys Registry Number Reaxys
52-86-8 CAS Registry Number KEGG COMPOUND
52-86-8 CAS Registry Number NIST Chemistry WebBook
52-86-8 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
10628896 PubMed citation Europe PMC
11304647 PubMed citation Europe PMC
25007358 PubMed citation Europe PMC
6725621 PubMed citation Europe PMC
7602118 PubMed citation Europe PMC
Last Modified
22 February 2017